Table 5 Characteristics of the propensity-matched cohort.
Received RT (N = 504) | RT omission (N = 504) | Standardized difference | |
|---|---|---|---|
Age | |||
Mean (SD) | 63.7 (11.0) | 64.0 (11.6) | 0.0340 |
≥70 yrs, N (%) | 207 (41.1%) | 204 (40.5%) | 0.0121 |
Comorbidities | 0.0097 | ||
0 | 398 (79.0%) | 396 (78.6%) | |
≥1 | 106 (21.0%) | 108 (21.4%) | |
Laterality | 0.0596 | ||
Left | 261 (51.8%) | 246 (48.8%) | |
Right | 243 (48.2%) | 258 (51.2%) | |
Hormone status | 0.0276 | ||
ER+ or PR+ | 382 (75.8%) | 376 (74.6%) | |
ER−/PR− | 122 (24.2%) | 128 (25.4%) | |
Treatment group | 0.0309 | ||
HS and received ET | 188 (37.3%) | 182 (36.1%) | |
HS, no ET | 194 (38.5%) | 194 (38.5%) | |
ER−/PR− | 122 (24.2%) | 128 (25.4%) | |
Tumor size | 0.0594 | ||
≤1 cm | 156 (31.0%) | 170 (33.7%) | |
>1–2 cm | 348 (69.0%) | 334 (66.3%) | |
Tumor grade | 0.0122 | ||
Grade 3 | 260 (51.6%) | 257 (51.0%) | |
Grade 1–2 | 221 (43.9%) | 224 (44.5%) | |
Unknown | 23 (4.5%) | 23 (4.5%) | |
Facility type | 0.0281 | ||
Academic | 147 (29.2%) | 150 (29.8%) | |
Other | 344 (68.3%) | 343 (68.1%) | |
Unknown | 13 (2.5%) | 11 (2.1%) | |
Race/ethnicity | 0.0734 | ||
NH-White | 407 (80.7%) | 393 (78.0%) | |
NH-Black | 43 (8.5%) | 50 (9.9%) | |
Hispanic | 25 (5.0%) | 30 (6.0%) | |
NH-Other | 25 (5.0%) | 26 (5.1%) | |
Unknown | 4 (0.8%) | 5 (1.0%) | |
Income status | 0.0082 | ||
<$46,000/yr | 282 (56.0%) | 284 (56.4%) | |
≥$46,000/yr | 204 (40.5%) | 202 (40.1%) | |
Unknown | 18 (3.5%) | 18 (3.5%) | |
No HSD | 0.0084 | ||
≥20% | 178 (35.3%) | 180 (35.7%) | |
<20% | 308 (61.1%) | 306 (60.7%) | |
Unknown | 18 (3.6%) | 18 (3.6%) | |
Distance to facility | |||
≥8.9 miles | 242 (48.0%) | 251 (49.8%) | 0.0357 |
<8.9 miles | 262 (52.0%) | 253 (50.2%) | |
Chemotherapy | 0.0787 | ||
Single-agent | 213 (42.2%) | 198 (39.3%) | |
Multi-agent | 283 (56.2%) | 294 (58.3%) | |
Not specified | 8 (1.6%) | 12 (2.4%) | |
